人骨骼肌线粒体H+-ATP合酶:在高脂血症和胰岛素抵抗中的作用
该研究分析了100例经代谢特征分析的人骨骼肌活检样本,发现2型糖尿病和肥胖通过不同机制损害H+-ATP合酶活性,并揭示IF1通过影响脂质代谢和TNF-α释放参与胰岛素抵抗。
要点
- 2型糖尿病和肥胖通过不同机制损害人骨骼肌H+-ATP合酶活性。
- IF1改变肥胖和糖尿病个体肌管中α-酮戊二酸和L-肉碱代谢,限制脂肪酸β-氧化。
- IF1可能作为脂质代谢和代谢紊乱的新型调节因子及治疗干预的潜在靶点。
核心结论
- IF1是脂质代谢和代谢紊乱的新型调节因子,并可能是治疗干预的潜在靶点。
研究设计与样本
- 研究分析了100例经代谢特征分析的人骨骼肌活检样本,并在来自同一活检样本的人肌管原代培养中过表达IF1。
主要发现
- 2型糖尿病和肥胖通过不同机制损害人骨骼肌H+-ATP合酶活性,分别表现为催化亚基减少76%和IF1表达增加280%。
- IF1改变肥胖个体(对照的84%)和糖尿病个体(对照的76%)肌管中α-酮戊二酸和L-肉碱代谢,导致脂肪酸β-氧化受限(对照的60%)及其胞质积累(对照的164%)。
- 上述事件导致TNF-α释放增强,对照组、肥胖组和2型糖尿病组分别为10 ± 2 pg/ml、27 ± 5 pg/ml和35 ± 4 pg/ml,可能促进胰岛素抵抗表型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Mitochondria are important regulators of the metabolic phenotype in type 2 diabetes. A key factor in mitochondrial physiology is the H+-ATP synthase. The expression and activity of its physiological inhibitor, ATPase inhibitory factor 1 (IF1), controls tissue homeostasis, metabolic reprogramming and signalling. We aimed to characterise the putative role of IF1 in mediating skeletal muscle metabolism in obesity and diabetes. METHODS: We examined the 'mitochondrial signature' of obesity and type 2 diabetes in a cohort of 100 metabolically characterised human skeletal muscle biopsy samples. The expression and activity of H+-ATP synthase, IF1 and key mitochondrial proteins were characterised, including their association with BMI, fasting plasma insulin, fasting plasma glucose and HOMA-IR. IF1 was also overexpressed in primary cultures of human myotubes derived from the same biopsies to unveil the possible role played by the pathological inhibition of the H+-ATP synthase in skeletal muscle. RESULTS: The results indicate that type 2 diabetes and obesity act via different mechanisms to impair H+-ATP synthase activity in human skeletal muscle (76% reduction in its catalytic subunit vs 280% increase in IF1 expression, respectively) and unveil a new pathway by which IF1 influences lipid metabolism. Mechanistically, IF1 altered cellular levels of α-ketoglutarate and L-carnitine metabolism in the myotubes of obese (84% of control) and diabetic (76% of control) individuals, leading to limited β-oxidation of fatty acids (60% of control) and their cytosolic accumulation (164% of control). These events led to enhanced release of TNF-α (10 ± 2 pg/ml, 27 ± 5 pg/ml and 35 ± 4 pg/ml in control, obese and type 2 diabetic participants, respectively), which probably contributes to an insulin resistant phenotype. CONCLUSIONS/INTERPRETATION: Overall, our data highlight IF1 as a novel regulator of lipid metabolism and metabolic disorders, and a possible target for therapeutic intervention.
引用
- Formentini L, Ryan AJ, Gálvez-Santisteban M, et al. Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia. 2017. PMID: 28770317. doi:10.1007/s00125-017-4379-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。